Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients.

Calsina B, Currás-Freixes M, Buffet A, Pons T, Contreras L, Letón R, Comino-Méndez I, Remacha L, Calatayud M, Obispo B, Martin A, Cohen R, Richter S, Balmaña J, Korpershoek E, Rapizzi E, Deutschbein T, Vroonen L, Favier J, de Krijger RR, Fassnacht M, Beuschlein F, Timmers HJ, Eisenhofer G, Mannelli M, Pacak K, Satrústegui J, Rodríguez-Antona C, Amar L, Cascón A, Dölker N, Gimenez-Roqueplo AP, Robledo M.

Genet Med. 2018 Jul 16. doi: 10.1038/s41436-018-0068-7. [Epub ahead of print]

PMID:
30008476
2.

Surviving ectopic Cushing's syndrome: Quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up.

Osswald A, Deutschbein T, Berr CM, Plomer E, Mickisch A, Ritzel K, Schopohl J, Beuschlein F, Fassnacht M, Hahner S, Reincke M.

Eur J Endocrinol. 2018 Jun 6. pii: EJE-18-0212. doi: 10.1530/EJE-18-0212. [Epub ahead of print]

PMID:
29875286
3.

[Thyroid gland and the heart : Pathophysiological background, diagnostic and therapeutic consequences].

Dischinger U, Fassnacht M.

Internist (Berl). 2018 Jul;59(7):668-673. doi: 10.1007/s00108-018-0441-2. Review. German.

PMID:
29796905
4.

Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours.

An Y, Reimann M, Masjkur J, Langton K, Peitzsch M, Deutschbein T, Fassnacht M, Rogowski-Lehmann N, Beuschlein F, Fliedner S, Stell A, Prejbisz A, Januszewicz A, Lenders J, Bornstein SR, Eisenhofer G.

Int J Obes (Lond). 2018 Mar 3. doi: 10.1038/s41366-018-0054-9. [Epub ahead of print]

PMID:
29717268
5.

Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.

Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M, Beuschlein F, Hahner S, Kroiss M, Fassnacht M; German ACC Study Group.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1686-1695. doi: 10.1210/jc.2017-02591.

PMID:
29452402
6.

Antwort.

Megerle F, Fassnacht M.

Dtsch Med Wochenschr. 2018 Feb;143(3):200. doi: 10.1055/s-0044-100145. Epub 2018 Feb 6. German. No abstract available.

PMID:
29409094
7.

High resolution tissue mass spectrometry imaging reveals a refined functional anatomy of the human adult adrenal gland.

Sun N, Wu Y, Nanba K, Sbiera S, Kircher S, Kunzke T, Aichler M, Berezowska S, Reibetanz J, Rainey WE, Fassnacht M, Walch A, Kroiss M.

Endocrinology. 2018 Jan 29. doi: 10.1210/en.2018-00064. [Epub ahead of print]

PMID:
29385420
8.

Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.

Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, Schirbel A, Deutschbein T, Williams TA, Rhayem Y, Quinkler M, Rayes N, Monticone S, Wild V, Gomez-Sanchez CE, Reis AC, Petersenn S, Wester HJ, Kropf S, Fassnacht M, Lang K, Herrmann K, Buck AK, Bluemel C, Hahner S.

Hypertension. 2018 Feb;71(2):317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975. Epub 2017 Dec 26.

9.

Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers.

Fenske WK, Schnyder I, Koch G, Walti C, Pfister M, Kopp P, Fassnacht M, Strauss K, Christ-Crain M.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):505-513. doi: 10.1210/jc.2017-01891.

PMID:
29267966
10.

[Pheochromocytoma - Current Recommendations on Diagnostics, Therapy and Follow-up].

Megerle F, Fassnacht M.

Dtsch Med Wochenschr. 2017 Dec;142(24):1797-1800. doi: 10.1055/s-0043-112777. Epub 2017 Dec 5. German.

PMID:
29207422
11.

ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas.

Laufs V, Altieri B, Sbiera S, Kircher S, Steinhauer S, Beuschlein F, Quinkler M, Willenberg HS, Rosenwald A, Fassnacht M, Ronchi CL.

Eur J Endocrinol. 2018 Feb;178(2):183-190. doi: 10.1530/EJE-17-0788. Epub 2017 Nov 29.

PMID:
29187510
12.

Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.

Henning JEK, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, Wild V, Schlötelburg W, Kroiss M, Perotti P, Rosenwald A, Berruti A, Fassnacht M, Ronchi CL.

J Clin Endocrinol Metab. 2017 Nov 1;102(11):4323-4332. doi: 10.1210/jc.2017-01624.

PMID:
29092062
13.

Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib.

Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl MC, Lapa C.

J Nucl Med. 2018 May;59(5):756-761. doi: 10.2967/jnumed.117.199778. Epub 2017 Oct 12.

PMID:
29025983
14.

Steroid Profiling for Adrenocortical Disorders: A Pathway for Omics-Based Diagnostics.

Eisenhofer G, Fassnacht M.

Clin Chem. 2017 Dec;63(12):1787-1789. doi: 10.1373/clinchem.2017.281048. Epub 2017 Oct 10. No abstract available.

PMID:
29018028
15.

Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.

Sbiera S, Sbiera I, Ruggiero C, Doghman-Bouguerra M, Korpershoek E, de Krijger RR, Ettaieb H, Haak H, Volante M, Papotti M, Reimondo G, Terzolo M, Luconi M, Nesi G, Mannelli M, Libé R, Ragazzon B, Assié G, Bertherat J, Altieri B, Fadda G, Rogowski-Lehmann N, Reincke M, Beuschlein F, Fassnacht M, Lalli E.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3491-3498. doi: 10.1210/jc.2017-00984.

PMID:
28911143
16.

Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study.

Baur J, Büntemeyer TO, Megerle F, Deutschbein T, Spitzweg C, Quinkler M, Nawroth P, Kroiss M, Germer CT, Fassnacht M, Steger U; German Adrenocortical Carcinoma Study Group.

BMC Cancer. 2017 Aug 4;17(1):522. doi: 10.1186/s12885-017-3506-z.

17.

Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome.

Di Dalmazi G, Quinkler M, Deutschbein T, Prehn C, Rayes N, Kroiss M, Berr CM, Stalla G, Fassnacht M, Adamski J, Reincke M, Beuschlein F.

Eur J Endocrinol. 2017 Aug;177(2):227-237. doi: 10.1530/EJE-17-0109. Epub 2017 May 31.

PMID:
28566446
18.

PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.

Currás-Freixes M, Piñeiro-Yañez E, Montero-Conde C, Apellániz-Ruiz M, Calsina B, Mancikova V, Remacha L, Richter S, Ercolino T, Rogowski-Lehmann N, Deutschbein T, Calatayud M, Guadalix S, Álvarez-Escolá C, Lamas C, Aller J, Sastre-Marcos J, Lázaro C, Galofré JC, Patiño-García A, Meoro-Avilés A, Balmaña-Gelpi J, De Miguel-Novoa P, Balbín M, Matías-Guiu X, Letón R, Inglada-Pérez L, Torres-Pérez R, Roldán-Romero JM, Rodríguez-Antona C, Fliedner SMJ, Opocher G, Pacak K, Korpershoek E, de Krijger RR, Vroonen L, Mannelli M, Fassnacht M, Beuschlein F, Eisenhofer G, Cascón A, Al-Shahrour F, Robledo M.

J Mol Diagn. 2017 Jul;19(4):575-588. doi: 10.1016/j.jmoldx.2017.04.009. Epub 2017 May 25.

19.

Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.

Rao D, Peitzsch M, Prejbisz A, Hanus K, Fassnacht M, Beuschlein F, Brugger C, Fliedner S, Langton K, Pamporaki C, Gudziol V, Stell A, Januszewicz A, Timmers HJLM, Lenders JWM, Eisenhofer G.

Eur J Endocrinol. 2017 Aug;177(2):103-113. doi: 10.1530/EJE-17-0077. Epub 2017 May 5.

20.

Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.

Roca E, Berruti A, Sbiera S, Rapa I, Oneda E, Sperone P, Ronchi CL, Ferrari L, Grisanti S, Germano A, Zaggia B, Scagliotti GV, Fassnacht M, Volante M, Terzolo M, Papotti M.

Endocr Relat Cancer. 2017 Jul;24(7):299-307. doi: 10.1530/ERC-17-0095. Epub 2017 Apr 21.

21.

Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.

Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM, Fassnacht M, Klink B, Lodish M, Stratakis CA, Huebner A, Fliedner S, Robledo M, Sinnott RO, Januszewicz A, Pacak K, Eisenhofer G.

J Clin Endocrinol Metab. 2017 Apr 1;102(4):1122-1132. doi: 10.1210/jc.2016-3829.

22.

Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.

Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, Mannelli M, Boscaro M, Arvat E, Tiberio G, Hahner S, Zaggia B, Porpiglia F, Volante M, Fassnacht M, Terzolo M.

J Clin Endocrinol Metab. 2017 Apr 1;102(4):1358-1365. doi: 10.1210/jc.2016-2894.

PMID:
28324035
23.

Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion.

Ruggiero C, Doghman-Bouguerra M, Sbiera S, Sbiera I, Parsons M, Ragazzon B, Morin A, Robidel E, Favier J, Bertherat J, Fassnacht M, Lalli E.

Sci Signal. 2017 Mar 7;10(469). pii: eaal2464. doi: 10.1126/scisignal.aal2464.

PMID:
28270555
24.

Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas.

Weigand I, Ronchi CL, Rizk-Rabin M, Dalmazi GD, Wild V, Bathon K, Rubin B, Calebiro D, Beuschlein F, Bertherat J, Fassnacht M, Sbiera S.

Sci Rep. 2017 Mar 8;7(1):49. doi: 10.1038/s41598-017-00125-8.

25.

[Adrenal incidentaloma - what to do and what not?]

Fassnacht M.

Dtsch Med Wochenschr. 2017 Feb;142(3):158-161. doi: 10.1055/s-0042-121731. Epub 2017 Feb 10. Review. German. No abstract available.

PMID:
28187478
26.

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.

Altieri B, Sbiera S, Della Casa S, Weigand I, Wild V, Steinhauer S, Fadda G, Kocot A, Bekteshi M, Mambretti EM, Rosenwald A, Pontecorvi A, Fassnacht M, Ronchi CL.

Oncotarget. 2017 Feb 7;8(6):9323-9338. doi: 10.18632/oncotarget.14067.

27.

Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas.

Sbiera S, Tryfonidou MA, Weigand I, Grinwis GC, Broeckx B, Herterich S, Allolio B, Deutschbein T, Fassnacht M, Meij BP.

PLoS One. 2016 Dec 22;11(12):e0169009. doi: 10.1371/journal.pone.0169009. eCollection 2016.

28.

DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.

Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, Barreau O, de la Villeon B, Faillot S, Hamzaoui N, Neou M, Perlemoine K, Rene-Corail F, Rodriguez S, Sibony M, Tissier F, Dousset B, Sbiera S, Ronchi C, Kroiss M, Korpershoek E, de Krijger R, Waldmann J, K D, Bartsch, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, Sturm N, Luconi M, Mantero F, Mannelli M, Cohen R, Kerlan V, Touraine P, Barrande G, Groussin L, Bertagna X, Baudin E, Amar L, Beuschlein F, Clauser E, Coste J, Bertherat J.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):923-932. doi: 10.1210/jc.2016-3205.

PMID:
27967600
29.

Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany.

Wendler J, Kroiss M, Gast K, Kreissl MC, Allelein S, Lichtenauer U, Blaser R, Spitzweg C, Fassnacht M, Schott M, Führer D, Tiedje V.

Eur J Endocrinol. 2016 Dec;175(6):521-529.

30.

Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.

Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, Wester HJ, Kropf S, Lapa C, Schirbel A, Buck AK, Herrmann K.

Clin Nucl Med. 2017 Jan;42(1):e29-e34.

PMID:
27819856
31.

Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.

Kroiss M, Sbiera S, Kendl S, Kurlbaum M, Fassnacht M.

Horm Cancer. 2016 Dec;7(5-6):345-355. Epub 2016 Sep 8.

PMID:
27631436
32.

Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.

Jung S, Nagy Z, Fassnacht M, Zambetti G, Weiss M, Reincke M, Igaz P, Beuschlein F, Hantel C.

Endocr Relat Cancer. 2016 Oct;23(10):825-37. doi: 10.1530/ERC-16-0249. Epub 2016 Aug 22.

33.

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.

Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW.

Cancer Cell. 2016 Aug 8;30(2):363. doi: 10.1016/j.ccell.2016.07.013. Epub 2016 Aug 8. No abstract available.

34.

Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas.

Calebiro D, Grassi ES, Eszlinger M, Ronchi CL, Godbole A, Bathon K, Guizzardi F, de Filippis T, Krohn K, Jaeschke H, Schwarzmayr T, Bircan R, Gozu HI, Sancak S, Niedziela M, Strom TM, Fassnacht M, Persani L, Paschke R.

J Clin Invest. 2016 Sep 1;126(9):3383-8. doi: 10.1172/JCI84894. Epub 2016 Aug 8.

35.

FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria.

Doghman-Bouguerra M, Granatiero V, Sbiera S, Sbiera I, Lacas-Gervais S, Brau F, Fassnacht M, Rizzuto R, Lalli E.

EMBO Rep. 2016 Sep;17(9):1264-80. doi: 10.15252/embr.201541504. Epub 2016 Jul 11.

36.

Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.

Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM.

Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467.

37.

Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation.

Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assié G, Weigand I, Calebiro D, Schwarzmayr T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK, Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM, Fassnacht M, Beuschlein F; European Network for the Study of Adrenocortical Tumors (ENSAT).

J Clin Endocrinol Metab. 2016 Sep;101(9):3526-38. doi: 10.1210/jc.2016-1586. Epub 2016 Jul 7.

PMID:
27389594
38.

Dyslipidemia causes overestimation of plasma mitotane measurements.

Paci A, Hescot S, Seck A, Jublanc C, Mercier L, Vezzosi D, Drui D, Quinkler M, Fassnacht M, Bruckert E, Lombès M, Leboulleux S, Broutin S, Baudin E.

Endocrinol Diabetes Metab Case Rep. 2016;2016:150135. doi: 10.1530/EDM-15-0135. Epub 2016 Jun 10.

39.

DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis.

Bancos I, Tamhane S, Shah M, Delivanis DA, Alahdab F, Arlt W, Fassnacht M, Murad MH.

Eur J Endocrinol. 2016 Aug;175(2):R65-80. doi: 10.1530/EJE-16-0297. Epub 2016 Jun 2. Review.

40.

MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis.

Dinnes J, Bancos I, Ferrante di Ruffano L, Chortis V, Davenport C, Bayliss S, Sahdev A, Guest P, Fassnacht M, Deeks JJ, Arlt W.

Eur J Endocrinol. 2016 Aug;175(2):R51-64. doi: 10.1530/EJE-16-0461. Epub 2016 Jun 2. Review.

41.

[Adrenocortical carcinoma and pregnancy].

Raffin-Sanson ML, Abiven G, Ritzel K, de Corbière P, Cazabat L, Zaharia R, Groussin L, Libe R, Bertherat J, Fassnacht M, Bertagna X.

Ann Endocrinol (Paris). 2016 Jun;77(2):139-47. doi: 10.1016/j.ando.2016.04.024. Epub 2016 May 9. Review. French.

PMID:
27172868
42.

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.

Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW.

Cancer Cell. 2016 May 9;29(5):723-736. doi: 10.1016/j.ccell.2016.04.002. Erratum in: Cancer Cell. 2016 Aug 8;30(2):363.

43.

Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301-2, A Promising Case of Drug Repurposing.

Kroiss M, Fassnacht M.

Endocrinology. 2016 May;157(5):1719-21. doi: 10.1210/en.2016-1210. No abstract available.

PMID:
27149038
44.

Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.

Werner RA, Kroiss M, Nakajo M, Mügge DO, Hahner S, Fassnacht M, Schirbel A, Bluemel C, Higuchi T, Papp L, Zsótér N, Buck AK, Bundschuh RA, Lapa C.

Endocrine. 2016 Sep;53(3):791-800. doi: 10.1007/s12020-016-0970-1. Epub 2016 May 2.

PMID:
27138903
45.

European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.

Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O; Guideline Working Group.

Eur J Endocrinol. 2016 May;174(5):G1-G10. doi: 10.1530/EJE-16-0033. Review.

46.

Expression of 11beta-hydroxysteroid-dehydrogenase type 2 in human thymus.

Almanzar G, Mayerl C, Seitz JC, Höfner K, Brunner A, Wild V, Jahn D, Geier A, Fassnacht M, Prelog M.

Steroids. 2016 Jun;110:35-40. doi: 10.1016/j.steroids.2016.03.019. Epub 2016 Mar 26. Review.

PMID:
27025972
47.

Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.

Kroiss M, Deutschbein T, Schlötelburg W, Ronchi CL, Neu B, Müller HH, Quinkler M, Hahner S, Heidemeier A, Fassnacht M; German Adrenocortical Carcinoma Study Group.

Horm Cancer. 2016 Jun;7(3):211-8. doi: 10.1007/s12672-016-0260-7. Epub 2016 Mar 9.

PMID:
26961793
48.

[Hormone therapy through changing times].

Reuter M, Fassnacht M.

Dtsch Med Wochenschr. 2016 Feb;141(3):161-4. doi: 10.1055/s-0041-109320. Epub 2016 Feb 3. German.

PMID:
26841174
49.

Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas.

Ronchi CL, Peverelli E, Herterich S, Weigand I, Mantovani G, Schwarzmayr T, Sbiera S, Allolio B, Honegger J, Appenzeller S, Lania AG, Reincke M, Calebiro D, Spada A, Buchfelder M, Flitsch J, Strom TM, Fassnacht M.

Eur J Endocrinol. 2016 Mar;174(3):363-72. doi: 10.1530/EJE-15-1064. Epub 2015 Dec 23.

50.

Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.

Kroiss M, Plonné D, Kendl S, Schirmer D, Ronchi CL, Schirbel A, Zink M, Lapa C, Klinker H, Fassnacht M, Heinz W, Sbiera S.

Eur J Endocrinol. 2016 Mar;174(3):343-53. doi: 10.1530/EJE-15-0946. Epub 2015 Dec 15.

Supplemental Content

Loading ...
Support Center